SVR12: 85% for daclatasvir vs 81% for telaprevir in GT1b patients; anemia less common with daclatasvir (-29.1% difference); SVR12 associated with IL28B genotype and cirrhosis status. This evidence concerns the gene IFNL3 and anemia.